DGAP-News
411
0 Kommentare
co.don AG to Participate in Webcast on Innovations in Regenerative Medicine & Curative Biologics
411 
0 KommentareDGAP-News: co.don Aktiengesellschaft / Key word(s): Conference
co.don AG to Participate in Webcast on Innovations in Regenerative
Medicine & Curative Biologics
07.10.2015 / 09:50
---------------------------------------------------------------------
Press release
co.don(R) AG to Participate in Webcast on Innovations in Regenerative
Medicine & Curative Biologics
Teltow, Germany - 07 October 2015 - Dr. Jeske Smink, Head of Scientific
Affairs at co.don, will participate in a BioPharma Dealmakers webcast,
sponsored in part by co.don, featuring four companies developing
regenerative medicine.
The webcast, part of the BioPharma Dealmakers series, is scheduled for
11:00 am ET on October 14. Webcast registration.
The webcast will explore some of the technologies and companies driving
this rapidly developing field of regenerative medicine. Participants will
learn about new approaches that have been developed to:
- Generate autologous cartilage cells for transplantation.
- Use pluripotent embryonic stem cell-derived oligodendrocyte progenitor
cells to treat spinal cord injuries.
- Enlist mAbs to slow or reverse senescence.
- Use 3D bioprinting to create tissues for use in drug discovery and
medical research.
The webcast will include a round table discussion and a Q&A session to
enable participants to contribute their own thoughts on this highly
innovative area of regenerative medicine.
Dr. Jeske Smink has extensive experience in the preclinical development of
cell therapeutics, specifically in quality aspects of cartilage cell
transplants. Other webcast participants include:
- Dr. Jane S. Lebkowski, Ph.D. is the President of R&D and Chief
Scientific Officer of Asterias Biotherapeutics.
- Dr. Lewis Gruber is CEO and Chief Scientific Officer of SIWA
Corporation.
- Dr. Sharon Collins Presnell is the CTO at Organovo, where she leads
their R&D group.
- Moderator : Gaspar Taroncher-Oldenburg, Ph.D. Dr. Taroncher-Oldenburg
is an independent consultant and former managing editor of SciBX:
Science-Business eXchange for Nature Publishing Group and the former
scientific editor at Nature Biotechnology.
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies
looking for commercial partnerships. Read the quarterly BioPharma
Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug
Discovery.
About co.don(R) AG: The biopharmaceutical company based near Berlin is one
of the leading specialists worldwide in cell cultivation for the
regenerative treatment of articular cartilage defects and spinal disc
defects. The company's pharmaceutical products are used to treat cartilage
damage. Left untreated, cartilage defects can often result in joint
replacement surgery. Orthopaedic, accident and neuro-surgeons are
increasingly applying these regenerative therapy methods. co.don(R) AG is
listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227).
Executive Board: Dirk Hessel (CEO) and Vilma Methner (COO, CSO).
More information is available www.codon.de
Contact:
Matthias Meißner, M.A. webinar@codon.de
Corporate Communications / IR / PR pr@codon.de
+49 +49 3328 43460
Fax: +49 03328 434643
---------------------------------------------------------------------
07.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: co.don Aktiengesellschaft
Warthestraße 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard);
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------
400495 07.10.2015
Press release
co.don(R) AG to Participate in Webcast on Innovations in Regenerative
Medicine & Curative Biologics
Teltow, Germany - 07 October 2015 - Dr. Jeske Smink, Head of Scientific
Affairs at co.don, will participate in a BioPharma Dealmakers webcast,
sponsored in part by co.don, featuring four companies developing
regenerative medicine.
The webcast, part of the BioPharma Dealmakers series, is scheduled for
11:00 am ET on October 14. Webcast registration.
The webcast will explore some of the technologies and companies driving
this rapidly developing field of regenerative medicine. Participants will
learn about new approaches that have been developed to:
- Generate autologous cartilage cells for transplantation.
- Use pluripotent embryonic stem cell-derived oligodendrocyte progenitor
cells to treat spinal cord injuries.
- Enlist mAbs to slow or reverse senescence.
- Use 3D bioprinting to create tissues for use in drug discovery and
medical research.
The webcast will include a round table discussion and a Q&A session to
enable participants to contribute their own thoughts on this highly
innovative area of regenerative medicine.
Dr. Jeske Smink has extensive experience in the preclinical development of
cell therapeutics, specifically in quality aspects of cartilage cell
transplants. Other webcast participants include:
- Dr. Jane S. Lebkowski, Ph.D. is the President of R&D and Chief
Scientific Officer of Asterias Biotherapeutics.
- Dr. Lewis Gruber is CEO and Chief Scientific Officer of SIWA
Corporation.
- Dr. Sharon Collins Presnell is the CTO at Organovo, where she leads
their R&D group.
- Moderator : Gaspar Taroncher-Oldenburg, Ph.D. Dr. Taroncher-Oldenburg
is an independent consultant and former managing editor of SciBX:
Science-Business eXchange for Nature Publishing Group and the former
scientific editor at Nature Biotechnology.
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies
looking for commercial partnerships. Read the quarterly BioPharma
Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug
Discovery.
About co.don(R) AG: The biopharmaceutical company based near Berlin is one
of the leading specialists worldwide in cell cultivation for the
regenerative treatment of articular cartilage defects and spinal disc
defects. The company's pharmaceutical products are used to treat cartilage
damage. Left untreated, cartilage defects can often result in joint
replacement surgery. Orthopaedic, accident and neuro-surgeons are
increasingly applying these regenerative therapy methods. co.don(R) AG is
listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227).
Executive Board: Dirk Hessel (CEO) and Vilma Methner (COO, CSO).
More information is available www.codon.de
Contact:
Matthias Meißner, M.A. webinar@codon.de
Corporate Communications / IR / PR pr@codon.de
+49 +49 3328 43460
Fax: +49 03328 434643
---------------------------------------------------------------------
07.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: co.don Aktiengesellschaft
Warthestraße 21
14513 Teltow
Germany
Phone: 03328 43460
Fax: 03328 434643
E-mail: info@codon.de
Internet: www.codon.de
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard);
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------
400495 07.10.2015
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Auch bei Lesern beliebt
